Terms: = Leukemia AND KAT6A
32 results:
1. Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of kat6a (MOZ) against leukemia by an isostere strategy.
Duan Y; Zhao Y; Li Z; Liu Z; Wang M; Wang X; Sun M; Song C; Yao Y
Eur J Med Chem; 2023 Nov; 260():115770. PubMed ID: 37651878
[TBL] [Abstract] [Full Text] [Related]
2. kat6a::EP300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report.
Hosahalli Vasanna S; Shah SD; Rohr BR; Roche B; Meyerson H; Pateva I
Medicine (Baltimore); 2023 Jul; 102(30):e34258. PubMed ID: 37505185
[TBL] [Abstract] [Full Text] [Related]
3. De novo monocytic-M5b AML with t(8;16) (p11.2; p13.3) kat6a/CREBBP fusion and FLT3-TKD mutation complicated by chemotherapy-induced Takotsubo cardiomyopathy.
Ananthaneni A; Benzar T; Hafiz N; Akabane H
BMJ Case Rep; 2023 Mar; 16(3):. PubMed ID: 36977512
[TBL] [Abstract] [Full Text] [Related]
4. A Case of Neonatal Myeloid Sarcoma.
Burdick H; Bormann J; Wagner K; Kerkvliet A
S D Med; 2022 Sep; 75(9):390-391. PubMed ID: 36881822
[TBL] [Abstract] [Full Text] [Related]
5. The histone acetyltransferase kat6a is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract] [Full Text] [Related]
6. Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling VY; Straube J; Godfrey W; Haldar R; Janardhanan Y; Cooper L; Bruedigam C; Cooper E; Tavakoli Shirazi P; Jacquelin S; Tey SK; Baell J; Huang F; Jin J; Zhao Y; Bullinger L; Bywater MJ; Lane SW
Leukemia; 2023 Jan; 37(1):143-153. PubMed ID: 36400926
[TBL] [Abstract] [Full Text] [Related]
7. kat6a and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract] [Full Text] [Related]
8. Distinctive Flow Cytometric and Mutational Profile of Acute Myeloid leukemia With t(8;16)(p11;p13) Translocation.
Aqil B; Gao J; Stalling M; Sukhanova M; Duncavage EJ; Lu X; Wolniak KL; Kreisel F; Yaseen NR
Am J Clin Pathol; 2022 May; 157(5):701-708. PubMed ID: 34698340
[TBL] [Abstract] [Full Text] [Related]
9. The role of MOZ/kat6a in hematological malignancies and advances in MOZ/kat6a inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract] [Full Text] [Related]
10. [Acute leukemia of infants and neonates].
Eguchi M
Rinsho Ketsueki; 2021; 62(8):1308-1318. PubMed ID: 34497221
[TBL] [Abstract] [Full Text] [Related]
11. miR-143-3p represses leukemia cell proliferation by inhibiting kat6a expression.
Xu D; Jiang J; He G; Zhou H; Ji C
Anticancer Drugs; 2022 Jan; 33(1):e662-e669. PubMed ID: 34459452
[TBL] [Abstract] [Full Text] [Related]
12. kat6a, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.
Liu W; Zhan Z; Zhang M; Sun B; Shi Q; Luo F; Zhang M; Zhang W; Hou Y; Xiao X; Li Y; Feng H
Theranostics; 2021; 11(13):6278-6292. PubMed ID: 33995658
[No Abstract] [Full Text] [Related]
13. Therapy-related Myeloid leukemia With the Translocation t(8;19)(p11;q13) Leading to a
Panagopoulos I; Andersen K; Ramslien LF; Ikonomou IM; Micci F; Heim S
Anticancer Res; 2021 Apr; 41(4):1753-1760. PubMed ID: 33813379
[TBL] [Abstract] [Full Text] [Related]
14. Acute Myeloid leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.
Conneely SE; Stevens AM
Curr Oncol Rep; 2021 Jan; 23(2):16. PubMed ID: 33439382
[TBL] [Abstract] [Full Text] [Related]
15. The key roles of the lysine acetyltransferases kat6a and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract] [Full Text] [Related]
16. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening.
Gier RA; Budinich KA; Evitt NH; Cao Z; Freilich ES; Chen Q; Qi J; Lan Y; Kohli RM; Shi J
Nat Commun; 2020 Jul; 11(1):3455. PubMed ID: 32661245
[TBL] [Abstract] [Full Text] [Related]
17. Src family kinase activity drives cytomegalovirus reactivation by recruiting MOZ histone acetyltransferase activity to the viral promoter.
Dupont L; Du L; Poulter M; Choi S; McIntosh M; Reeves MB
J Biol Chem; 2019 Aug; 294(35):12901-12910. PubMed ID: 31273084
[TBL] [Abstract] [Full Text] [Related]
18. Transcriptome analysis identifies key regulators and networks in Acute myeloid leukemia.
Ye J; Luo D; Yu J; Zhu S
Hematology; 2019 Dec; 24(1):487-491. PubMed ID: 31210592
[TBL] [Abstract] [Full Text] [Related]
19. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/kat6a-CREBBP in adults.
Xie W; Hu S; Xu J; Chen Z; Medeiros LJ; Tang G
Ann Hematol; 2019 May; 98(5):1149-1157. PubMed ID: 30759270
[TBL] [Abstract] [Full Text] [Related]
20. NEAT1-TFE3 and kat6a-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
[TBL] [Abstract] [Full Text] [Related]
[Next]
